SCHEMBL279719

SCHEMBL279719

Cc1ccc(-c2c(C)c(C)n(N)c2C#N)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.39
▸ KDM4E B2RXH2 7/20 0.39
▸ HPGD P15428 6/20 0.39
▸ GAA P10253 2/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ CYP1A2 P05177 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ CYP2A6 P11509 1/20 0.36
▸ RXFP1 Q9HBX9 3/20 0.35
▸ NPSR1 Q6W5P4 3/20 0.35
▸ HTT P42858 2/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ LMNA P02545 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ PDE9A O76083 3/20 0.33
▸ ADORA1 P30542 2/20 0.33
▸ PDE1C Q14123 2/20 0.33
▸ GRIA2 P42262 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL279720 0.81 GRIA2 (0.40) ALDH1A1KDM4EHPGDGAAMEN1
SCHEMBL12872136 0.68 ADORA1 (0.45) ALDH1A1KDM4EHPGDGAAMEN1
SCHEMBL10118041 0.66 — —
SCHEMBL942 0.62 TSHR (0.46) ALDH1A1KDM4EHPGDGAAMEN1
SCHEMBL21385864 0.62 ACHE (0.61) ALDH1A1HPGDCYP2C9LMNATDP1
SCHEMBL28349524 0.61 ALDH1A1 (0.42) ALDH1A1KDM4EHPGDGAAMEN1
SCHEMBL29152122 0.61 PDE9A (0.44) ALDH1A1KDM4EHPGDGAAMEN1
SCHEMBL13753709 0.60 ALDH1A1 (0.54) ALDH1A1KDM4EHPGDGAAMEN1
SCHEMBL12377032 0.60 CYP2A6 (0.84) ALDH1A1GAACYP2A6ERBB2HSD17B10
SCHEMBL91813 0.60 CYP2A6 (0.84) ALDH1A1GAACYP2A6ERBB2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8829185-B2 Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis BAYER HEALTHCARE LLC (US) 2014-09-09 — — US disclosed
US-20120165314-A1 SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS BAYER HEALTHCARE LLC (US) 2012-06-28 — — US disclosed
US-8133995-B2 Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis BAYER HEALTHCARE LLC (US) 2012-03-13 — — US disclosed
US-20090281079-A1 Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated With Angiogenesis BAYER HEALTHCARE LLV (US) 2009-11-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165314-A1 SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS CDK4, FLT4, CDKL4 ALDH1A1 3137/4885KDM4E 1151/4885HPGD 253/4885
US-20090281079-A1 Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated With Angiogenesis CDK4, FLT4, CDKL4 ALDH1A1 3137/4885KDM4E 1151/4885HPGD 253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback